DHAid (Algal Oil Omega-3 DHA)

DHAid is a branded algal oil concentrate delivering docosahexaenoic acid (DHA), a long-chain omega-3 fatty acid derived from microalgae rather than fish. DHA integrates into neuronal phospholipid membranes, supporting synaptic fluidity and neuroprotective signaling via the BDNF and neuroprotectin D1 pathways.

Origin & History

DHAid is a branded algal oil rich in docosahexaenoic acid (DHA), derived from heterotrophic marine microalgae Schizochytrium limacinum (also called Aurantiochytrium limacinum) through controlled fermentation. The microalgae are harvested by filtration, freeze-dried, and processed into oil through mixing with vegetable oil carriers, offering a sustainable fish-free omega-3 source with DHA comprising over 20% of dry cell weight.

Historical & Cultural Context

No historical or traditional medicine use documented for DHAid, as it is a modern biotechnological product. The research indicates this is a contemporary development in sustainable omega-3 production rather than a traditional remedy.

Health Benefits

• No specific health benefits documented - research dossier lacks clinical evidence for DHAid
• General DHA benefits cannot be attributed without product-specific studies
• No human trials, RCTs, or meta-analyses found in the provided research
• No PubMed citations available for health outcomes
• Evidence quality: Absent for this branded ingredient

How It Works

DHA, the active constituent in DHAid, incorporates into phosphatidylserine and phosphatidylethanolamine fractions of neuronal cell membranes, enhancing membrane fluidity and modulating voltage-gated ion channels critical for synaptic transmission. DHA also serves as a precursor to neuroprotectin D1 (NPD1), a lipid mediator that suppresses pro-apoptotic signaling and NF-κB-driven neuroinflammation. Additionally, DHA upregulates BDNF expression, supporting neurogenesis and long-term potentiation in the hippocampus.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were found for DHAid branded algal oil in the research dossier. While general algal DHA sources are noted for omega-3 production, no PubMed PMIDs, study designs, sample sizes, or specific outcomes are available for this branded product.

Clinical Summary

DHAid as a specific branded ingredient lacks published human clinical trials, randomized controlled studies, or peer-reviewed meta-analyses establishing product-specific efficacy or dosing benchmarks. General algal-oil DHA research, including studies such as the Yurko-Mauro et al. (2010) RCT (n=485), has demonstrated improvements in episodic memory in older adults with age-related cognitive decline using 900 mg DHA daily over 24 weeks. However, these findings cannot be directly attributed to DHAid without formulation-matched studies confirming equivalent bioavailability and DHA concentration. The current evidence base for this specific branded ingredient must be characterized as insufficient for definitive efficacy claims.

Nutritional Profile

DHAid is a branded algal oil ingredient derived from the microalga Schizochytrium sp., primarily providing docosahexaenoic acid (DHA), a long-chain omega-3 polyunsaturated fatty acid (C22:6, n-3). Typical DHA concentration ranges from 35–45% of total oil content (approximately 350–450 mg DHA per gram of oil), though some concentrated forms may reach 50%+ DHA by weight. The oil is predominantly composed of triglycerides, with minor amounts of other fatty acids including docosapentaenoic acid (DPA n-6, typically 5–15%), palmitic acid (C16:0, ~10–20%), and trace amounts of EPA (<1–3%). Being an algal-derived source, it contains negligible EPA compared to fish oil, making it a DHA-dominant omega-3 source. Micronutrient content is minimal as it is a refined oil; however, it naturally contains small amounts of carotenoids (astaxanthin and beta-carotene in trace quantities depending on processing) and tocopherols (vitamin E, often added at ~0.5–1.5 mg/g as mixed tocopherols for antioxidant stabilization). No significant fiber, protein, carbohydrates, vitamins, or minerals are present. The oil is cholesterol-free and suitable for vegetarian/vegan applications. Bioavailability notes: DHA in triglyceride form (as found in algal oil) generally demonstrates superior bioavailability compared to ethyl ester forms, with studies on generic algal DHA triglycerides showing ~50–70% greater absorption versus ethyl esters when consumed with a fat-containing meal. Absorption is significantly enhanced (up to 2–3 fold) when consumed with dietary fat (~10–15 g). Algal-derived DHA has been shown in general (non-brand-specific) studies to raise blood DHA levels comparably to fish-derived DHA. No product-specific bioavailability or pharmacokinetic studies for the DHAid branded ingredient were identified in the available research dossier.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are available for DHAid in the current research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient research data to determine synergistic ingredients

Safety & Interactions

Algal oil DHA at doses up to 3,000 mg/day is generally recognized as safe (GRAS) by the FDA, with the most commonly reported adverse effects being mild gastrointestinal discomfort, fishy aftertaste, and loose stools at higher doses. DHA can potentiate the anticoagulant effects of warfarin, aspirin, and clopidogrel by inhibiting thromboxane A2 synthesis, increasing bleeding risk, particularly at doses exceeding 2,000 mg/day. Pregnant and breastfeeding individuals may use algal DHA as a fish-free omega-3 source, with 200–300 mg/day considered safe and beneficial for fetal neurodevelopment per EFSA guidance. Individuals on immunosuppressants or antihypertensive medications should consult a physician, as high-dose DHA may modestly lower blood pressure and alter immune eicosanoid profiles.